Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Recommendation of “Moderate Buy” from Analysts

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) has been given an average rating of “Moderate Buy” by the eleven brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $41.7778.

A number of research analysts have issued reports on OLMA shares. UBS Group began coverage on Olema Pharmaceuticals in a research note on Wednesday, January 7th. They issued a “buy” rating and a $45.00 target price for the company. JPMorgan Chase & Co. boosted their price objective on Olema Pharmaceuticals from $29.00 to $32.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Oppenheimer raised their target price on shares of Olema Pharmaceuticals from $45.00 to $48.00 and gave the stock an “outperform” rating in a report on Thursday, December 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a report on Thursday, January 22nd. Finally, The Goldman Sachs Group increased their price objective on shares of Olema Pharmaceuticals from $26.00 to $38.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th.

Olema Pharmaceuticals Stock Up 0.4%

Shares of NASDAQ OLMA opened at $23.75 on Friday. Olema Pharmaceuticals has a 52-week low of $2.86 and a 52-week high of $36.26. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.03 and a current ratio of 8.03. The stock has a market cap of $1.63 billion, a P/E ratio of -12.70 and a beta of 1.89. The firm has a 50 day moving average price of $27.15 and a 200 day moving average price of $16.02.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.05). Analysts expect that Olema Pharmaceuticals will post -2.33 EPS for the current year.

Insider Transactions at Olema Pharmaceuticals

In other Olema Pharmaceuticals news, insider David C. Myles sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $27.60, for a total value of $1,380,000.00. Following the sale, the insider owned 542,761 shares in the company, valued at approximately $14,980,203.60. The trade was a 8.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Naseem Zojwalla sold 99,509 shares of the firm’s stock in a transaction that occurred on Tuesday, December 23rd. The stock was sold at an average price of $27.66, for a total transaction of $2,752,418.94. Following the transaction, the insider directly owned 4,488 shares of the company’s stock, valued at $124,138.08. This represents a 95.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 765,501 shares of company stock valued at $22,052,432. 16.36% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in OLMA. Ameritas Investment Partners Inc. boosted its stake in shares of Olema Pharmaceuticals by 55.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock worth $26,000 after buying an additional 2,168 shares during the last quarter. Farther Finance Advisors LLC boosted its position in Olema Pharmaceuticals by 602.9% during the second quarter. Farther Finance Advisors LLC now owns 6,839 shares of the company’s stock valued at $29,000 after purchasing an additional 5,866 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in Olema Pharmaceuticals by 9,476.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after purchasing an additional 1,232 shares in the last quarter. FNY Investment Advisers LLC increased its position in shares of Olema Pharmaceuticals by 100.0% during the 2nd quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock worth $42,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Torren Management LLC acquired a new position in shares of Olema Pharmaceuticals during the 4th quarter worth approximately $44,000. Institutional investors own 91.78% of the company’s stock.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.